In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Omrix Biopharmaceuticals nets $51.4mm in FOPO

Executive Summary

Recently public Omrix Biopharmaceuticals (fibrin sealants and biosurgical products) brought in $51.4mm in a follow-on offering of 1.7mm shares (including the overallotment) at $32 apiece. Selling stockholders netted $22.6mm through the sale of an additional 750k shares.
Deal Industry
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
    • Surgical Equipment & Devices
      • Surgical Sealants
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies